Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Gains from Sales and Divestitures (2016 - 2025)

Bio-Techne's quarterly Gains from Sales and Divestitures came in at $134000.0 in Q2 2025, up 3.88% year-on-year from $129000.0 in Q2 2024, and up 3.88% quarter-over-quarter from $129000.0 in Q2 2024.

Bio-Techne has reported Gains from Sales and Divestitures for 10 years, with the latest figure at $134000.0 in Q2 2025.

  • For the quarter ending Q2 2025, Gains from Sales and Divestitures rose 3.88% year-over-year to $134000.0; the trailing twelve-month figure through Jun 2025 stood at $134000.0 (up 3.88% YoY), and the FY2025 full-year result was $134000.0, up 3.88% from the prior year.
  • Gains from Sales and Divestitures for Q2 2025 stood at $134000.0, up from $129000.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $145000.0 in Q2 2022, with the low at $65000.0 in Q2 2021.
  • Average Gains from Sales and Divestitures over 5 years is $119200.0, with a median of $129000.0 recorded in 2024.
  • Year-over-year, Gains from Sales and Divestitures jumped 261.11% in 2021 and declined 15.17% in 2023.
  • Tracing TECH's Gains from Sales and Divestitures over 5 years: stood at $65000.0 in 2021, then surged by 123.08% to $145000.0 in 2022, then slipped by 15.17% to $123000.0 in 2023, then grew by 4.88% to $129000.0 in 2024, then climbed by 3.88% to $134000.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $134000.0 (Q2 2025), $129000.0 (Q2 2024), and $123000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 134,000.00
Jun 30, 2025 134,000.00
Jun 30, 2024 129,000.00
Jun 30, 2024 129,000.00
Jun 30, 2023 123,000.00
Jun 30, 2023 123,000.00
Jun 30, 2022 145,000.00
Jun 30, 2022 145,000.00
Jun 30, 2021 65,000.00
Jun 30, 2021 65,000.00
Jun 30, 2020 18,000.00
Jun 30, 2020 18,000.00
Jun 30, 2019 20,000.00
Jun 30, 2019 20,000.00
Jun 30, 2018 16,000.00
Jun 30, 2018 16,000.00
Jun 30, 2017 9,000.00
Jun 30, 2017 9,000.00
Jun 30, 2016 5,000.00
Jun 30, 2016 5,000.00